In the ongoing fight to treat Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) approved the drug Leqembi as a possible treatment on Jan. 6.
The approval is under the FDA’s Accelerated Approval pathway, which approves drugs for serious conditions where there is an unmet medical need.
While this may sound like promising news, you may be wondering: What is the new FDA-approved Alzheimer's drug and how does it slow cognitive decline?
Leqembi is the second drug of a new category of approved medications to treat the disease, according to a press release from the FDA.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it,” says Billy Dunn, director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, in the press release. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of ...
